Study summary

Obinutuzumab also improved lupus beyond the kidneys

ALLEGORY trial · Phase 3 · Published March 2026, New England Journal of Medicine; FDA decision expected December 2026

23.1percentage points more people responded than with placebo

What was tested

Obinutuzumab against placebo, added to standard therapy, for active systemic lupus erythematosus.

What they found

About 23.1 percentage points more people had a meaningful response (SLE Responder Index-4) at 52 weeks.
The FDA accepted an application in April 2026.

What it means

Could make obinutuzumab one of the few drugs approved for both general lupus and lupus nephritis.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.